Medicxi-backed Vicebio: vaccines with stability, production advantages

A University of Queensland spinout has won the backing of Medicxi to advance vaccines using a conformational technology that could enhance the products’ stability, as well as their immunogenicity and safety.

The European venture firm has committed €18 million ($18.3 million) thus far to newly launched Vicebio Ltd., with the aim of starting a clinical trial in 2H23 of a vaccine to prevent respiratory syncytial virus (RSV)...